Psoriatic arthritis (PsA) affects nearly 30% of people living with psoriasis and impacts millions worldwide. The disease causes chronic joint inflammation, stiffness, swelling, fatigue, and progressive joint damage that can significantly reduce quality of life.
Just 15 years ago, treatment options were limited mainly to conventional disease-modifying drugs such as methotrexate. Many patients continued to experience disease progression despite therapy. Today, advances in immunology and biologic medicine have transformed the treatment landscape, with multiple targeted therapies offering higher response rates and improved long-term outcomes.
The global psoriatic arthritis treatment market is estimated to exceed $12 billion in 2026, driven by the growing adoption of biologics and targeted therapies.
The Brands Driving Innovation
Several drug brands are consistently recognized by rheumatologists and dermatologists as innovation leaders due to their novel mechanisms, extensive clinical programs, and strong patient outcomes.
| Brand | Company | Mechanism | Initial Approval for PsA |
|---|---|---|---|
| BIMZELX | UCB | Dual IL-17A and IL-17F inhibitor | 2024 |
| TREMFYA | Johnson & Johnson | IL-23 inhibitor | 2020 |
| SKYRIZI | AbbVie | IL-23 inhibitor | 2022 |
| COSENTYX | Novartis | IL-17A inhibitor | 2016 |
| TALTZ | Eli Lilly | IL-17A inhibitor | 2017 |
| RINVOQ | AbbVie | JAK inhibitor | 2021 |
These therapies target key inflammatory pathways that drive joint damage and skin disease, enabling more personalized treatment strategies.
BIMZELX Is Setting a New Benchmark
One of the most significant recent innovations is BIMZELX (bimekizumab), developed by UCB.
Unlike earlier IL-17 inhibitors that target only IL-17A, BIMZELX inhibits both IL-17A and IL-17F. Researchers believe these two cytokines work together to drive inflammation, making dual inhibition a promising strategy.
The Phase III BE OPTIMAL trial evaluated more than 850 patients with active PsA. At Week 16, approximately 44% of patients receiving BIMZELX achieved ACR50 compared with around 10% in the placebo group.
The more recent BE BOLD head-to-head study generated considerable attention across the rheumatology community. At Week 16, 49.1% of patients treated with BIMZELX achieved ACR50 compared with 38.4% of patients receiving SKYRIZI. Complete skin clearance (PASI100) was achieved by 53.4% versus 46.6%, respectively.
These results have positioned BIMZELX among the most closely watched biologic innovations in active PsA treatment.
TREMFYA Focuses on Long-Term Joint Protection
TREMFYA (guselkumab) has established itself as a major innovation in the IL-23 inhibitor category.
The DISCOVER-1 and DISCOVER-2 Phase III studies enrolled more than 1,100 patients with active PsA. In these studies, nearly 52% to 64% of patients achieved ACR20 responses at Week 24 compared with approximately 22% to 33% for placebo.
A major milestone came in 2026 when TREMFYA received an FDA label expansion showing evidence of inhibiting structural joint damage progression. This achievement made TREMFYA the first and only IL-23 inhibitor with this specific claim at the time.
For physicians treating patients at risk of irreversible joint destruction, this additional evidence strengthened TREMFYA’s position as a leading innovative therapy.
SKYRIZI Continues Rapid Growth
SKYRIZI (risankizumab) has become one of the fastest-growing immunology brands worldwide.
The Phase III KEEPsAKE-1 and KEEPsAKE-2 trials included more than 1,400 patients with active PsA. At Week 24, approximately 57% of patients receiving SKYRIZI achieved ACR20 compared with about 34% receiving placebo.
The therapy has also demonstrated strong skin outcomes. In psoriasis studies, many patients achieved PASI90 and PASI100 responses, helping SKYRIZI gain widespread adoption among both rheumatologists and dermatologists.
AbbVie reported annual SKYRIZI global sales exceeding $13 billion in 2025, making it one of the highest-performing immunology products in the industry.
COSENTYX Remains a Category Pioneer
COSENTYX (secukinumab) was the first IL-17 inhibitor approved for psoriatic arthritis and remains one of the most prescribed biologics globally.
Since its initial approval, more than one million patients across approved indications have been treated with COSENTYX worldwide. Long-term extension studies have demonstrated durable efficacy extending beyond five years in many patients.
Clinical trials showed ACR20 responses ranging from approximately 50% to 60% depending on dose and patient population. The drug also demonstrated significant reductions in enthesitis, dactylitis, and skin symptoms.
Even as newer therapies enter the market, COSENTYX continues to serve as a benchmark against which emerging treatments are measured.
TALTZ Delivers Strong Joint and Skin Responses
TALTZ (ixekizumab) has become another major IL-17 inhibitor in the PsA market.
The SPIRIT clinical development program enrolled more than 1,400 patients across multiple studies. In pivotal trials, nearly 58% to 62% of patients achieved ACR20 responses at Week 24 compared with approximately 30% for placebo.
TALTZ has demonstrated particularly strong performance in patients with significant skin involvement, making it a valuable option for individuals requiring control of both joint and dermatologic symptoms.
Oral Innovation Through RINVOQ
While biologics dominate the market, oral targeted therapies continue to gain attention.
RINVOQ (upadacitinib) is a selective JAK inhibitor that offers patients a once-daily oral treatment alternative. The SELECT-PsA clinical program enrolled more than 2,000 patients across multiple studies.
In pivotal trials, approximately 70% of patients receiving RINVOQ achieved ACR20 responses compared with roughly 36% in placebo groups. Some analyses also demonstrated efficacy comparable to certain biologic therapies.
The convenience of an oral option has contributed significantly to RINVOQ’s growing adoption.
Innovation in active psoriatic arthritis treatment has accelerated rapidly over the past decade. What was once a disease managed primarily through symptom control is now being addressed through targeted therapies designed to achieve deeper remission and prevent irreversible joint damage.
BIMZELX is attracting attention through dual IL-17A and IL-17F inhibition and strong head-to-head data. TREMFYA is advancing long-term joint protection through structural damage evidence. SKYRIZI continues to expand its global presence with blockbuster sales and strong efficacy. COSENTYX remains a pioneering force with extensive real-world experience, while TALTZ and RINVOQ provide additional innovative options for diverse patient needs.
As clinical research continues and new mechanisms emerge, the future of psoriatic arthritis treatment is increasingly focused on achieving sustained remission, preserving joint function, and improving the lives of millions of patients worldwide.
Get Easy Access
Access our exclusive, data-rich dashboard dedicated to the therapeutics area sector – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Healthcare WebWire is a part of Towards Healthcare Research and Consulting is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium